Cost-effectiveness of immunoglobulin M-enriched immunoglobulin (Pentaglobin) in the treatment of severe sepsis and septic shock.

Abstract

PURPOSE:

To measure the cost-effectiveness of a specific polyclonal intravenous immune globulin preparation (Pentaglobin) in adult patients treated for severe sepsis and septic shock.

MATERIALS AND METHODS:

Effectiveness data from a meta-analysis of 9 randomized trials (N=435) were used to populate a decision model to estimate the cost-effectiveness of Pentaglobin and its comparator standard therapy from the hospital perspective in Germany.

PRIMARY OUTCOME:

all-cause morality; secondary outcome: intensive care unit (ICU) length of stay. Benefit was expressed as lives saved (LS). Published cost data were applied to assess differences in ICU treatment costs. Cost-effectiveness was calculated as incremental cost per LS.

RESULTS:

Pentaglobin reduced the risk of mortality (P<.001) but had no effect on ICU length of stay. A baseline risk of mortality of 0.4434 (risk ratio=0.5652; absolute risk reduction=0.1928; number-needed-to-treat=5.19) increased ICU treatment costs with Pentaglobin by 2,037 (22,711 vs 24,747) with a cost per LS of 10,565. Sensitivity analyses on baseline mortality risk (95% confidence interval 0.3293-0.5162) and risk ratio (95% confidence interval 0.4306-0.7420) yielded a cost per LS range of 5,715 to 28,443 with a 56.3% probability of cost-effectiveness of 12,000 or less.

CONCLUSIONS:

Pentaglobin is a promising adjuvant therapy both clinically and economically for treatment of adults with severe sepsis and septic shock.

• Authors: Aileen R Neilson, Hilmar Burchardi, Heinz Schneider
• Journal: Journal of critical care (J Crit Care) Vol. 20 Issue 3 Pg. 239-49 (Sep 2005) ISSN: 0883-9441 [Print] United States
• PMID: 16253792 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulin A
• Immunoglobulin M
• pentaglobulin

Topics

• Cost-Benefit Analysis
• Decision Support Techniques
• Drug Costs
• Germany
• Humans
• Immunoglobulin A (economics, therapeutic use)
• Immunoglobulin M (economics, therapeutic use)
• Intensive Care Units
• Length of Stay
• Sepsis (drug therapy, economics, mortality)
• Shock, Septic (drug therapy, economics, mortality)